Ipsen
CompanyFranceFounded 1929
Ipsen develops one asset, in phase 3 (elafibranor in primary biliary cholangitis). Mostly small molecule acting on lipid and ceramide metabolism, PPARD and PPARA; based in France, founded in 1929.
- 1
- Asset
- Furthest
- Phase 3
- 8
- Trials
- 0
- Signals
Pipeline
1Dual PPAR alpha/delta agonist that regulates bile acid synthesis, inflammation, and fibrosis
Phase 3, Small molecule, Lipid and ceramide metabolism, PPARD, primary biliary cholangitis, primary sclerosing cholangitis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials12
- Signals1
- Similar companies6
Updated 10 Oct 2026 · 29 sources